Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46.2M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
14.7M
-
Shares change
-
+1.25M
-
Total reported value, excl. options
-
$527M
-
Value change
-
+$44.8M
-
Put/Call ratio
-
0.38
-
Number of buys
-
51
-
Number of sells
-
-31
-
Price
-
$35.94
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q2 2019
97 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q2 2019.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.7M shares
of 46.2M outstanding shares and own 31.74% of the company stock.
Largest 10 shareholders include MENORA MIVTACHIM HOLDINGS LTD. (2.95M shares), Consonance Capital Management LP (1.43M shares), WELLINGTON MANAGEMENT GROUP LLP (1.42M shares), BlackRock Inc. (1.34M shares), HIGHLINE CAPITAL MANAGEMENT, L.P. (1.01M shares), Wildcat Capital Management, LLC (843K shares), FMR LLC (588K shares), CREDIT SUISSE AG/ (573K shares), MEITAV DASH INVESTMENTS LTD (566K shares), and Clal Insurance Enterprises Holdings Ltd (554K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.